- Sanofi (NASDAQ:SNY) will help manufacture 125M doses of the coronavirus vaccine developed by Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX), while its own vaccine candidate faces delays.
- BioNTech will initially produce the vaccines at Sanofi facilities in Frankfurt, starting in the summer.
- Financial details of the agreement were not revealed.
- Sanofi and partner GlaxoSmithKline (NYSE:GSK) will start a new phase-2 trial of their COVID-19 vaccine next month, Sanofi said.
- Last month, the two companies said that their vaccine won’t be ready until late 2021 after their shot resulted in an "insufficient" response in older adults.